Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)

CT-P13 subcutaneous (SC), an SC formulation of the intravenous (IV) infliximab biosimilar CT-P13 IV, creates a unique exposure profile. The LIBERTY studies aimed to demonstrate superiority of CT-P13 SC vs placebo as maintenance therapy in patients with Crohn’s disease (CD) and ulcerative colitis (UC...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Gastroenterology (New York, N.Y. 1943) N.Y. 1943), 2024-10, Vol.167 (5), p.919-933
Hauptverfasser:	Hanauer, Stephen B., Sands, Bruce E., Schreiber, Stefan, Danese, Silvio, Kłopocka, Maria, Kierkuś, Jarosław, Kulynych, Roman, Gonciarz, Maciej, Sołtysiak, Artur, Smoliński, Patryk, Srećković, Slobodan, Valuyskikh, Ekaterina, Lahat, Adi, Horyński, Marek, Gasbarrini, Antonio, Osipenko, Marina, Borzan, Vladimir, Kowalski, Maciej, Saenko, Daria, Sardinov, Ruslan, Lee, Sang Joon, Kim, Sunghyun, Bae, Yunju, Lee, Sunhee, Lee, Seulgi, Lee, Joon Ho, Yang, Siyoung, Lee, Jimin, Lee, Juhyun, Kim, Jong Min, Park, Gahee, Sandborn, William J., Colombel, Jean-Frederic
Format:	Artikel
Sprache:	eng
Schlagworte:	Crohn's Disease CT-P13 SC Infliximab-dyyb LIBERTY Ulcerative Colitis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!